Evidence map›Paper›PMID 38673974›Full record

ReviewInternational journal of molecular sciences2024

Nutritional Support: The Use of Antioxidants in Inflammatory Bowel Disease.

Sara Jarmakiewicz-Czaja, Katarzyna Ferenc, Aneta Sokal-Dembowska, Rafał Filip

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Selenium: A Key Element in Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sara Jarmakiewicz-CzajaInstitute of Health Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.ORCID 0000-0001-6896-4744
Katarzyna FerencInstitute of Medicine, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.ORCID 0000-0001-5255-9648
Aneta Sokal-DembowskaInstitute of Health Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.ORCID 0000-0003-4727-8766
Rafał FilipInstitute of Medicine, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.ORCID 0000-0002-5954-151X
University of Rzeszów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The problem of treating inflammatory bowel disease continues to be a topic of great interest for researchers. Despite the complexity surrounding their treatment and strategies to prolong periods of remission, there is a promising exploration of various compounds that have potential in combating inflammation and alleviating symptoms. Selenium, calcium, magnesium, zinc, and iron are among these compounds, offering a glimpse of hope in the treatment of IBD. These essential minerals not only hold the promise of reducing inflammation in these diseases, but also show the potential to enhance immune function and possibly influence the balance of intestinal microflora. By potentially modulating the gut microbiota, they may help support overall immune health. Furthermore, these compounds could play a crucial role in mitigating inflammation and minimising complications in patients with IBD. Furthermore, the protective effect of these compounds against mucosal damage in IBD and the protective effect of calcium itself against osteoporosis in this group of patients are notable.

Indexed as

AntioxidantsGastrointestinal MicrobiomeInflammatory Bowel DiseasesAnimalsCalciumDietary SupplementsHumansMagnesiumNutritional SupportSeleniumZincAntioxidantsCalciumMagnesiumSeleniumZincantioxidantsCrohn’s diseaseinflammatory bowel diseasesmineralsulcerative colitis

Identifiers

PMID38673974
PMCPMC11050446
OpenAlexW4394880481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.